A MULTICENTER, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, PARALLEL GROUP TRIAL TO INVESTIGATE THE EFFICACY AND SAFETY OF SPM 927 (200MG/DAY AND 400MG/DAY) AS ADJUNCTIVE THERAPY IN SUBJECTS WITH PARTIAL SEIZURES WITH OR WITHOUT SECONDARY GENERALIZATION: